Ronald L. Dubowy

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano et al. · Journal of Clinical Oncology · 2017 · 345 citations · Full text

Hematological Malignancy, Immunohematology, Momelotinib 200 +13

Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 [see comments]

Yaddanapudi Ravindranath, Esteban Abella, J. Krischer et al. · Blood · 1992 · 257 citations · Full text

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Susan O’Brien, Nicole Lamanna, Thomas J. Kipps et al. · Blood · 2015 · 239 citations · Full text

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell et al. · The Lancet Oncology · 2022 · 217 citations

Hematological Malignancy, Lymphoid Neoplasia, Transplantation +10

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Jeffrey A. Jones, Tadeusz Robak, Jennifer R. Brown et al. · The Lancet Haematology · 2017 · 198 citations

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia +10